Alzheimer's disease (AD) remains a major cause of morbidity and mortality worldwide, and
despite extensive research, only a few drugs are available for management of the disease …

There is substantial evidence that cholinergic system function impairment plays a significant
role in many central nervous system (CNS) disorders. During the past three decades …

The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in
Alzheimer's disease and schizophrenia. We present data on the effect of KarXT (xanomeline …

Abstract Purpose of Review Lewy body dementia (LBD) encompasses dementia with Lewy
bodies (DLB) and Parkinson's disease dementia (PDD). This article will emphasize potential …

Copy number variants indicating loss of function in the DLG2 gene have been associated
with markedly increased risk for schizophrenia, autism spectrum disorder, and intellectual …

We investigated the genome of a 5-year-old male who presented with global developmental
delay (motor, cognitive, and speech), hypotonia, possibly ataxia, and cerebellar hypoplasia …

The basal forebrain cholinergic nuclei (BFCN) provide the main cholinergic input to
prefrontal cortices, the hippocampi, and amygdala. These structures are highly relevant for …

Purpose To review the available evidence on the impact of muscarinic receptor modulation
on cardiovascular control in humans. Methods In this narrative Review we summarize data …

Introduction This study examined the safety and pharmacodynamic effects of selective
muscarinic M1 receptor orthosteric agonist HTL0018318 in 60 patients with mild‐to …

Muscarinic acetylcholine receptors expressed in the central nervous system mediate various
functions, including cognition, memory, or reward. Therefore, muscarinic receptors represent …